NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
National Institutes of Health · Opportunity PAR-25-026
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this opportunity
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
Award history
No reliable public award data exists for this opportunity's Assistance Listing — some agencies record their awards under a different listing number than the one they put on Grants.gov. Rather than show a misleading zero, we show nothing.
Don't want to hunt for grants like this one? Get free deadline alerts for your state and focus areas.
Consultant or grant writer? See the client-ready Opportunity Brief for this grant — actual award sizes vs. the advertised ceiling, who wins, printable "prepared for your client" version.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| NIH Director’s Pioneer Award (DP1 Clinical Trial Optional) | National Institutes of Health | September 9, 2026 0d left | $700k | Nonprofits |
| Fiscal Year 2027 Expanding Nutrition Services | Health Resources and Services Administration | September 9, 2026 0d left | $350k | |
| NIH Director’s Early Independence Award (DP5 Clinical Trial Optional) | National Institutes of Health | September 10, 2026 1d left | $350k | Nonprofits |
| Improving the Capacity of Tribal Communities to Identify Emerging Drug Threats | Office of National Drug Control Policy | September 13, 2026 4d left | $300k | Nonprofits |